Provider Networks
Expert articles and analysis related to provider networks.
AI Summary — Last 7 Days
CMS’s proposed MA/Part D rule puts network adequacy enforcement back in the foreground, with new requirements aimed at cleaning up Medicare Advantage provider directories, giving beneficiaries remedies when they rely on inaccurate network information, and increasing PBM transparency—changes that could materially affect payer-provider contracting, steerage, and attribution reliability for VBC arrangements (AHA summary). At the same time, CMMI’s ACCESS Model and renewed discussion of social risk adjustment point to a broader Trump CMS push to pair technology-enabled chronic disease care with more precise payment design, while provider networks face added pressure from 340B disputes, drug-pricing reforms, and MA market exits that could narrow access and complicate population health management ([Manatt on ACCESS](https://news.google.com/rss/articles/CBMisAFBVV95cUxNazJfTS1VTWVKU1ZrcDZ0VXFyZXQ4RTNFQ1Y2al9pWmRVSVA1dk40QmNaSU9CMzlTRDdydjd0Tk1TTkVNYzBrZXRxSy02eTFmUXdPMTEyeTFaM1M2SXVoWkFpTThFdmJ1TU5RWUREbVMtWTN6
Related Articles
Prescription Drug Affordability Boards Reshape Reimbursement While Leaving Core Problems Unresolved
State boards were established to address legitimate concerns about prescription drug costs and patient affordability, but they don’t use the right measures to assess what patients actually pay. The po...
PBM influence is only growing, American Medical Association report finds
The 10 largest PBMs are also part of a company that owns a health plan.
Brand Drugmakers Raise Median Net Launch Price of New Drugs 35% In Just Three Years
Brand Drugmakers Raise Median Net Launch Price of New Drugs 35% In Just Three Years AHIP
Inside the 340B Rebate Pilot Standoff: Court, Congress, Drugmakers
Administration Finalizes Medicare Part B International Reference Pricing Model
Administration Finalizes Medicare Part B International Reference Pricing Model Health Affairs
Administration Finalizes Medicare Part B International Reference Pricing Model
Administration Finalizes Medicare Part B International Reference Pricing Model Health Affairs
AHA urges court to reject drug industry intervention in 340B rebate program case
AHA urges court to reject drug industry intervention in 340B rebate program case American Hospital Association
Price of new drugs up 35% since 2022: 6 things hospital leaders should know
Price of new drugs up 35% since 2022: 6 things hospital leaders should know Becker's Hospital Review
The U.S. Pays Triple What Other Countries Pay for Drugs. Here’s What the Evidence Says About Fixing It.
The U.S. Pays Triple What Other Countries Pay for Drugs. Here’s What the Evidence Says About Fixing It. AcademyHealth
Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025
Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025 American Hospital Association